Mesa Laboratories, Inc. Form 10-Q Summary
Reporting period: Quarter and six months ended September 30, 2014, within the fiscal year ending March 31, 2015. The request metadata identifies “2013 Q2,” but the filing itself clearly reports September 30, 2014 results and compares them with September 30, 2013.
Business Context
Mesa develops and sells quality-control products through three reporting segments: Biological Indicators, Instruments, and Continuous Monitoring. Its products serve regulated healthcare, pharmaceutical, medical device, industrial, environmental, and laboratory markets. The company emphasizes niche markets, regulatory-driven demand, recurring disposable products, and acquisition-led growth.
Key Financial Metrics
| Metric | Three Months Ended September 30 | Six Months Ended September 30 |
|---|---|---|
| Revenue | $18.5 million, up 46% | $34.9 million, up 46% |
| Gross profit | $11.1 million | $20.8 million |
| Gross margin | 60%, unchanged | 60%, unchanged |
| Operating income | $4.9 million, up 95% | $8.0 million, up 43% |
| Net income | $3.1 million, up 58% | $4.9 million, up 30% |
| Net margin | 17%, versus 15% | 14%, versus 16% |
| Diluted EPS | $0.84, versus $0.54 | $1.35, versus $1.06 |
| Operating cash flow | Not separately provided | $3.7 million, versus $5.6 million |
Segment revenue for the quarter was $6.4 million for Biological Indicators, $9.1 million for Instruments, and $3.0 million for Continuous Monitoring. Foreign revenue was $8.8 million for the quarter and $16.8 million for the six-month period; no individual foreign country exceeded 10% of total revenue.
Balance Sheet, Debt, and Liquidity
- Cash and cash equivalents were $3.7 million at September 30, 2014, compared with $5.6 million at March 31, 2014.
- Total assets increased to $112.1 million from $97.5 million, primarily reflecting acquisitions and related goodwill and intangible assets.
- Working capital was $17.5 million, compared with $16.4 million at March 31, 2014.
- Total debt was $25.8 million, consisting of $11.5 million under the revolving line of credit and $14.3 million under a term loan. Debt was $16.5 million at March 31, 2014.
- The credit facility was amended in April 2014 to add a $15.0 million term loan and extend the maturity date to June 30, 2017. The facility is secured by the company’s assets.
- Mesa was in compliance with its funded-debt-to-EBITDA and fixed-charge coverage covenants at September 30, 2014. As of October 31, 2014, outstanding indebtedness was $28.5 million and unused facility capacity was $5.0 million.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven by acquisitions, organic growth, price increases, and expansion in existing and new markets.
- Biological Indicators revenue increased 7% in the quarter and 18% for six months; management cited the Amilabo acquisition, organic growth, pricing, and volume efficiencies.
- Instruments revenue increased 36% in the quarter and 29% for six months, primarily due to the BGI acquisition and organic growth, partially offset by the NuSonics disposition.
- Continuous Monitoring contributed $3.0 million of quarterly revenue and $5.3 million for six months, compared with no comparable prior-year revenue, following the Amega and TempSys acquisitions.
- Operating expenses increased 22% in the quarter and 46% for six months. Increases reflected personnel, acquisition costs, amortization, research and development, and infrastructure investments.
- Net income benefited from higher revenue and gross profit, while the prior-year period included a $468,000 gain from the NuSonics disposition and a $1.1 million sales-tax accrual, making comparisons less recurring.
- Operating cash flow declined because of increased accounts receivable and inventory associated with acquisitions and growth.
Acquisitions, Outlook, Risks, and Unusual Items
- Mesa acquired BGI on April 15, 2014, for $10.3 million. The acquisition added $5.7 million of intangible assets and $3.3 million of goodwill.
- Mesa also completed the Amilabo acquisition in April 2014 and had previously acquired Amega and TempSys in November 2013. Aggregate acquisition spending during the six months was $13.8 million.
- After quarter-end, Mesa acquired PCD-LLC’s process challenge device business for $5.25 million, including $5.0 million paid at closing, with up to $1.5 million of contingent consideration. The acquisition was financed in part with a $5.0 million line-of-credit draw.
- Management expects continued growth from biological indicators, instruments, continuous monitoring, new products, and further acquisitions. It stated that biological-indicator demand remains strong, while instrument and monitoring demand may be more sensitive to economic conditions and customer capital spending.
- Management expects an effective tax rate of approximately 35.3% going forward. Six-month net income included $2.2 million of non-cash amortization of intangible assets.
- An ERP system implementation over the next six to nine months may require significant cash expenditures.
- Contingent consideration exposure includes up to $10.0 million related to Amega and up to $6.7 million related to the Bios acquisition. Recorded contingent consideration totaled $1.6 million at September 30, 2014.
- Mesa continued addressing historical state sales-tax obligations. The filing states that several state returns were completed, while work continued in remaining states; the ultimate liability may change.
- Open purchase orders for routine supplies and inventory totaled approximately $7.7 million, payable in less than one year.
- Management reported no material changes to previously disclosed risk factors, no derivative instruments, and minimal foreign-currency and commodity-market exposure.
- The board declared a quarterly dividend of $0.16 per share in October 2014, payable December 15, 2014.
Facts Investors Should Verify
- Whether acquisition-related revenue growth and integration benefits persist after the BGI, Amilabo, Amega, TempSys, and PCD transactions.
- The effect of higher debt, required amortization, variable interest rates, and limited unused credit capacity on liquidity.
- Whether Continuous Monitoring margins improve after integration activities substantially concluded.
- The ultimate amount and timing of contingent consideration payments and historical state sales-tax liabilities.
- The cash requirements and implementation risks associated with the ERP upgrade and planned acquisitions.
- Whether operating cash flow improves as acquisition-related receivables and inventories normalize.
- The filing’s internal-control disclosures, including the statement that acquired operations representing 10% of six-month revenue were excluded from management’s control evaluation.